Latest Conference Articles

The placenta plays a major role in preeclampsia but is difficult to access. Investigators have turned to the eye, the choroid in particular, looking for clues about this serious condition.

Pinakin Davey, DO, PhD, discusses the findings of his study comparing reliability of testing methodologies for visual acuity and contrast sensitivity at ARVO 2019.

People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.

The ZEBRA study found that ziv-aflibercept was non-inferior to aflibercept and ranibizumab, and was more cost-effective.

Mia Woodward, MD, discusses the findings of her study which explored the possible over prescription and use of opioids post-corneal surgery.

The field has a growing demand of care, and dropping rate of new specialists. The solution can start at medical schools.

Mia Woodward, MD, discusses her study examining the the inclusion of women and minorities in National Eye Institute clincal trials.

Investigators examined both basal and reflex tears from patients with and without Parkinson disease, in search of a potential biomarker.

Investigator Lim sees hope that the EyeArt AI system will be able to screen more patients for diabetic retinopathy and help prevent blindness.

Investigators found that children who experienced concussion-related visual dysfunction had a recovery time nearly twice that of those who did not.

William Freeman, MD, of UCSD and Shiley Eye Institute, discusses the importance of creating treatments for eye diseases that make compliance easier for patients.

William Freeman, MD, discusses the results of a study he led and other potential treatments for geographic atrophy from a session he hosted at ARVO 2019.

Pinakin Davey, DO, PhD, sat down with MD Magazine® at ARVO 2019 to discuss a study he led testing a handheld tonometer for testing IOP.

The artificial intelligence system, EyeArt, was able to detect diabetic retinopathy with a sensitivity of 95.5% and specificity of 86%.

Jonathan Myers, MD, of the Wills Eye Hospital, discusses a study examining the rate of car accidents among glaucoma patients.

After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.

With 8.5% of the global population having diabetes, there is a growing unmet need for diabetic retinopathy screening. Artificial intelligence may help close the gap.

Aflibercept not only significantly improved patients’ DRSS scores, but it also reduced vision-threatening complications by 75% compared to placebo.

The trial examined 2 doses of aflibercept versus sham in patients with good visual acuity and no center-involving diabetic macular edema.

Investigators reported improvements in BCVA and in central subfield thickness, but noted decreases in superficial and deep capillary density.

A recent study found that early intervention before vision loss does little for patients compared to those who do not receive preemptive treatment.

PANORAMA is the first prospective study of high-risk patients with non-proliferative diabetic retinopathy, but not DME, in the anti-VEGF era.

After analyzing information from a cohort of more than 380,000, investigators found an association between chronic illnesses and visual impairment.

Approximately half of all patients with diabetes suffer from keratopathy, yet diagnoses are still underwhelming. Annual screenings need to become more standard.

Jason Hsu, MD, and his colleagues at the Wills Eye Hospital presented a study at ARVO 2019 regarding short-term outcomes of patients, with nAMD, who switched from afliberecept to ranibizumab.

Mia Woodward, MD, discusses the future of telehealth in ophthalmology and the biggest issues that need to be corrected going forward.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

No significant differences in cardiovascular outcomes among patients receiving different GLP-1 agonists including exenatide extended-release, exenatide immediate-release, liraglutide, albiglutide, and dulaglutide.